Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FORTY SEVEN, INC.

 SummaryNewsRatingsCompany 
Company
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189,... 
More about the company
Ratings of Forty Seven, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about FORTY SEVEN, INC.
2020FORTY SEVEN, INC. : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2020FORTY SEVEN, INC.(NASDAQGS : FTSV) dropped from S&P Global BMI Index
CI
2020FORTY SEVEN, INC.(NASDAQGS : FTSV) dropped from S&P TMI Index
CI
2020FORTY SEVEN : Management's Discussion and Analysis of Financial Condition and Re..
AQ
2020Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results..
GL
2020Forty Seven, Inc. Reports Earnings Results for the Fourth Quarter Ended Decem..
CI
2020FORTY SEVEN ALERT : Bragar Eagel & Squire, P.C. Investigates Sale of FTSV and En..
PR
2020Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fa..
GL
2020Certain Stock Options of Forty Seven, Inc. are subject to a Lock-Up Agreement..
CI
2020Certain Common Stock of Forty Seven, Inc. are subject to a Lock-Up Agreement ..
CI
2020Monteverde & Associates PC Announces an Investigation of Forty Seven, Inc. - ..
PR
2020Thermo Fisher agrees to buy genetic tester Qiagen in $11.5 billion deal
RE
2020Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline
RE
2020FORTY SEVEN : Gilead to Acquire Forty Seven for $4.9 Billion
BU
2020FORTY SEVEN, INC. : Entry into a Material Definitive Agreement, Other Events, Fi..
AQ
More news
News in other languages on FORTY SEVEN, INC.
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2020EN DIRECT DES MARCHES : Safran, Veolia, Saint-Gobain, Lagardère, Korian, GTT,..
2020STOCK MARKET PARIS : Vent de panique sur les marchés financiers
More news
Managers and Directors
Andrew D. Dickinson President, Treasurer & Director
Kyle C. Elrod Senior Vice President-Planning & Operations
Brett A. Pletcher Secretary & Director
Christina Carlson Director
Hannah Deresiewicz Investor Relations Contact
Sector and Competitors
1st jan.Capi. (M$)
FORTY SEVEN, INC.142.60%4 599
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850